

Form PTO-1390 P22033.P06		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER P22033	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/069,111	
INTERNATIONAL APPLICATION NO. PCT/JP00/05920		INTERNATIONAL FILING DATE 31 August 2000		PRIORITY DATE CLAIMED 31 August 1999	
TITLE OF INVENTION METHOD OF ANALYZING MUTUAL INTERACTION BETWEEN PROTEIN AND MOLECULE					
APPLICANT(S) FOR DO/EO/US Hiroshi YANAGAWA and Naoto NEMOTO					
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.</p> <ol style="list-style-type: none"> 1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). 5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)) 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (U.S.C. 371(c)(5)). <p>Items 11 to 16 below concern other document(s) or information included:</p> <ol style="list-style-type: none"> 11. Assignee: <u>MITSUBISHI CHEMICAL CORPORATION of Tokyo, JAPAN</u> 12. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. <input type="checkbox"/> A FIRST preliminary amendment. <input checked="" type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> Figure of Drawing to be published: <u>3</u> 18. <input checked="" type="checkbox"/> Other items or information: Cover Letter. Response to Paper Dated May 1, 2002 and Statement that the Content of Paper and Computer Readable Copies are the Same. Diskette Containing Sequence Listing. Paper/Written copies of Sequence Listing (5 pages). Copy of form PCT/DO/EO/905. 					

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/069,11		INTERNATIONAL APPLICATION NO. PCT/JP00/05920		ATTORNEY'S DOCKET NUMBER P22033	
--	--	---	--	------------------------------------	--

19. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search report has been prepared by the EPO or JPO. \$ 890.00 International preliminary examination fee paid to USPTO (37 CFR 1.482). \$ 710.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO(37 CFR 1.445(a)(2)). \$ 740.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO. \$1,040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). \$ 100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS		PTO USE ONLY	

Surcharge of \$130.00 for furnishing the oath or declaration later than ___ 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 0.00	
---	--	--	--	---------	--

Claims	Number Filed	Number Extra	RATE		
Total Claims	40 - 40 =	0	X \$18.00	\$ 0.00	
Independent Claims	6 - 6 =	0	X \$84.00	\$ 0.00	
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$130.00	

___ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 0.00	
SUBTOTAL =				\$130.00	

Processing fee of \$130.00 for furnishing the English translation later than ___ 20 ___ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
Extension of Time fee in the amount of \$				\$ 0.00	
TOTAL NATIONAL FEE =				\$130.00	

Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$130.00	

07/02/2002 LLANDGRA 00000102 10069111				Amount to be refunded	\$
01 FL:154 130.00 OP				Charged	\$

a. ☒ A check in the amount of \$130.00 to cover the above fees is enclosed.

b. ___ Please charge my Deposit Account No. ___ in the amount of \$___ to cover the above fees.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0089.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055
AT THE PRESENT ADDRESS OF:

Bruce H. Bernstein
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

SIGNATURE
 Bruce H. Bernstein
 NAME
 29,027 *Reg No. 31,296*
 REGISTRATION NUMBER

P22033.P07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hiroshi YANAGAWA et al.

Serial No : 10/069,111
(National Stage of PCT/JP00/05920)

I.A. Filed : August 31, 2000

For : METHOD FOR ANALYZING INTERACTION BETWEEN PROTEIN AND MOLECULE

COVER LETTER

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In order to comply with the requirements (copy enclosed) for the submission of an executed declaration of the International Application set forth in the Notification mailed May 1, 2002 which sets a one month period of response until July 1, 2002, Applicants hereby submit:

- Transmittal Letter to the United States Designated/Elected Office Concerning a Filing

Under 35 U.S.C. 371;

- an executed Declaration and Power of Attorney;
- a Response to Paper Dated May 1, 2002 and Statement that the Content of Paper and Computer Readable Copies are the Same;

- a Diskette Containing Sequence Listing;
- Paper/Written copies of Sequence Listing (5 pages);
- a check in the amount of \$130.00 to cover the surcharge for late filing of the Declaration.

Also enclosed is:


- a Supplemental Preliminary Amendment; and

- an Information Disclosure Statement, form PTO-1449, and references cited.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 19-0089.

Should the Examiner have any questions, he is invited to contact the undersigned at the below listed number.

Respectfully submitted,
Hiroshi YANAGAWA et al.


Bruce H. Bernstein
Reg. No. 29,027 *Reg no 31,296*

June 28, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke
Reston, VA 20191
(703) 716-1191

PTO/PCT Rec'd 28 JUN 2002

P22033.A04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hiroshi YANAGAWA et al.

Art Group Unit: Not Yet Known

Appl. No. : 10/069,111
(National Stage of PCT/JP00/05920)

Examiner: Not Yet Known

Filed : February 27, 2002
(I.A. Filed August 31, 2000)

For : METHOD FOR ANALYZING INTERACTION BETWEEN
PROTEIN AND MOLECULE

**RESPONSE TO PAPER DATED MAY 1, 2002
AND
STATEMENT THAT THE CONTENT OF THE PAPER AND
COMPUTER READABLE COPIES ARE THE SAME**

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Paper dated May 1, 2002 (copy enclosed), which includes a printout indicating that the computer readable form of the sequence listing filed with the application was not in the correct format, Applicants submit herewith paper and computer readable copies of the sequence listing. Inasmuch as the two-month period for response was set in the Paper to expire on July 1, 2002, this response is being filed in a timely manner. The Commissioner is hereby authorized to charge any necessary fees, such as any necessary extension of time fees, to Deposit Account No. 19-0089.

P22033.A04


In accordance with 37 C.F.R. 1.821(f), the undersigned hereby states that the information recorded in the computer readable form is identical to the written sequence listing.

Applicants hereby state that the submission, filed in accordance with 37 C.F.R. 1.821(h), herein does not include new matter.

In view of the above, Applicants respectfully submit that the objection to the sequence listing should be withdrawn, and Applicants respectfully request an action on the merits for the present application.

Should there be any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted,
Hiroshi YANAGAWA et al.

A handwritten signature in black ink, appearing to read "Bruce H. Bernstein", written over a horizontal line.

Bruce H. Bernstein
Reg. No. 29,027

Reg No 45905

June 27, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191




UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/069,111	Hiroshi Yanagawa	P22033

 07055
 GREENBLUM & BERNSTEIN, P.L.C.
 1941 ROLAND CLARKE PLACE
 RESTON, VA 20191

INTERNATIONAL APPLICATION NO.	
PCT/JP00/05920	
I.A. FILING DATE	PRIORITY DATE
08/31/2000	08/31/1999

 CONFIRMATION NO. 3232
 371 FORMALITIES LETTER


Date Mailed: 05/01/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

RECEIVED

MAY 09 2002

GREENBLUM & BERNSTEIN PLC

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- \$130 Surcharge for providing the oath or declaration later than the appropriate 30 months from the priority date (37 CFR 1.492(e)) is required.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR

THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - **APPLICANT MUST PROVIDE:**
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$130** for a Large Entity:

- **\$130** Late oath or declaration Surcharge.
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PAULETTE R KIDWELL

Telephone: (703) 305-3656

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/069,111	PCT/JP00/05920	P22033